Selective Estrogen Receptor Modulators

"Selective Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Descriptor ID	D020845
MeSH Number(s)	D06.347.360.827 D27.505.696.399.450.360.827
Concept/Terms	Selective Estrogen Receptor Modulators Selective Estrogen Receptor Modulators SERMs Estrogen Receptor Modulators, Selective Selective Estrogen Receptor Modulator SERM Estrogen Receptor Modulator, Selective

Below are MeSH descriptors whose meaning is more general than "Selective Estrogen Receptor Modulators".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Estrogen Receptor Modulators [D06.347.360]
Selective Estrogen Receptor Modulators [D06.347.360.827]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Estrogen Receptor Modulators [D27.505.696.399.450.360]
Selective Estrogen Receptor Modulators [D27.505.696.399.450.360.827]

Below are MeSH descriptors whose meaning is related to "Selective Estrogen Receptor Modulators".

Below are MeSH descriptors whose meaning is more specific than "Selective Estrogen Receptor Modulators".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Selective Estrogen Receptor Modulators" by people in this website by year, and whether "Selective Estrogen Receptor Modulators" was a major or minor topic of these publications.

Bar chart showing 17 publications over 12 distinct years, with a maximum of 3 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2002	2	0	2
2004	2	1	3
2005	1	0	1
2006	1	0	1
2007	0	1	1
2010	1	1	2
2014	1	0	1
2017	0	1	1
2018	0	1	1
2019	1	0	1
2022	0	2	2

Below are the most recent publications written about "Selective Estrogen Receptor Modulators" by people in Profiles.

Diot C, Garc?a-Gonz?lez AP, Vieira AF, Walker M, Honeywell M, Doyle H, Ponomarova O, Rivera Y, Na H, Zhang H, Lee M, Olsen CP, Walhout AJM. Bacterial diet modulates tamoxifen-induced death via host fatty acid metabolism. Nat Commun. 2022 09 23; 13(1):5595.

View in: PubMed
Messier TL, Boyd JR, Gordon JAR, Tye CE, Page NA, Toor RH, Zaidi SK, Komm BS, Frietze S, Stein JL, Lian JB, Stein GS. Epigenetic and transcriptome responsiveness to ER modulation by tissue selective estrogen complexes in breast epithelial and breast cancer cells. PLoS One. 2022; 17(7):e0271725.

View in: PubMed
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 09 03; 322(9):857-867.

View in: PubMed
Carrasquillo R, Chu K, Ramasamy R. Novel Therapy for Male Hypogonadism. Curr Urol Rep. 2018 Jun 09; 19(8):63.

View in: PubMed
Chakhtoura M, Sriram U, Heayn M, Wonsidler J, Doyle C, Dinnall JA, Gallucci S, Roberts RA. Bisphenol A Does Not Mimic Estrogen in the Promotion of the In Vitro Response of Murine Dendritic Cells to Toll-Like Receptor Ligands. Mediators Inflamm. 2017; 2017:2034348.

View in: PubMed
Fantasia HC. Treatment of dyspareunia secondary to vulvovaginal atrophy. Nurs Womens Health. 2014 Jun-Jul; 18(3):237-41.

View in: PubMed
Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011 Feb; 26(2):397-404.

View in: PubMed
Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Effect of Raloxifene on all-cause mortality. Am J Med. 2010 May; 123(5):469.e1-7.

View in: PubMed
Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2009 Oct 14; 302(14):1573-9.

View in: PubMed
Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Feb 01; 26(4):549-55.

View in: PubMed

People

Explore

Similar Concepts

Top Journals